Compare DigitalOcean Holdings Inc (DOCN) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DigitalOcean Holdings Inc vs Incyte Corporation — how do they compare? DigitalOcean Holdings Inc trades at $126.65 (market cap $14.57B), while Incyte Corporation trades at $112.75 (market cap $22.85B). The key difference: Incyte Corporation is the larger of the two by market cap, and DigitalOcean Holdings Inc is more actively traded (2,261,786 versus 1,927,029). Which is the better fit depends on your goals — on Pluang, investors hold DigitalOcean Holdings Inc for 43 Days and Incyte Corporation for 33 Days on average.
| DOCN | INCY | |
|---|---|---|
Market Cap | $14.57B | $22.85B |
Volume | 2,261,786 | 1,927,029 |
Sector | Technology | Health |
52-Week High | $181.29 | $129.93 |
52-Week Low | $37.30 | $83.80 |
Typical Hold Time | 43 Days | 33 Days |
Enterprise Value | $15.33B | $18.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DigitalOcean trades at $127.28, down 2.89% today, with strong technical support at $126 and resistance at $130. The company shows robust revenue growth from $576M in 2022 to $901M in 2025, with net income turning positive to $259M. Recent AI-focused product launches including Agent Droplets and Managed Agents position the company for continued growth in cloud services.
Despite high valuation multiples (P/E 57.85, P/S 14.34), analyst consensus remains bullish with a $172.73 price target representing 36% upside. Key risks include capital intensity from expansion and high debt levels, while institutional accumulation and consistent earnings beats support the growth narrative.
Incyte (INCY) trades at $113.44, up 0.63% with a bullish technical outlook despite mixed moving average signals. The company shows strong fundamentals with $5.14B revenue, 27.71% net margin, and robust cash flow of $1.41B. Recent FDA approval for Atebrioz and pipeline expansion beyond JAKAFI position the company for growth, with analysts projecting $5.8B revenue and $1.6B net income for 2026.
The investment case centers on Incyte's successful diversification strategy and strong profitability metrics, though investors face risks from JAKAFI patent expiration in 2029 and near-term earnings volatility. With 52% analyst buy ratings and a $132.43 consensus price target representing 17% upside, the stock offers growth potential but requires monitoring of pipeline execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About DigitalOcean Holdings Inc
DigitalOcean Holdings Inc is a cloud computing platform offering on-demand infrastructure and platform tools for developers, start-ups and small and medium-sized businesses. The customers use the platform for a wide range of cases, such as web and mobile applications, website hosting, e-commerce, media and gaming, personal web projects, and managed services, among many others. The group has a business presence in North America, Europe, Asia and other countries.
Read more on DOCN →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
